Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

Obesity is a growing concern in India, contributing to conditions such as type-2 diabetes and cardiovascular ... BT: Are there other drugs in Eli Lilly’s pipeline targeting obesity or related ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...

The healthcare giant has several exciting late-stage pipeline candidates, too, especially in the weight loss market. Eli Lilly's long, successful history of dominating the diabetes market is more ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... strategy for Kailera’s pipeline of GLP-1 candidates ...

Eli Lilly and Company (NYSE ... helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas. Lilly expects to add 750 highly skilled ...